Aminophylline showed no clear difference in hospital admissions compared with placebo (moderate certainty).
Aminophylline showed no clear difference in tremor compared with placebo (low certainty).
Aminophylline probably leads to higher vomiting compared with placebo (moderate certainty).
Aminophylline probably leads to higher arrhythmia/palpitations compared with placebo (moderate certainty).
Irinotecan + targeted therapy showed no clear difference in overall survival compared with irinotecan (low certainty).
Irinotecan + targeted therapy probably leads to lower progression‐free survival compared with irinotecan (moderate certainty).
Irinotecan + targeted therapy leads to higher overall tumour response compared with irinotecan (high certainty).
Irinotecan + targeted therapy leads to higher severe adverse effects compared with irinotecan (high certainty).
Lesinurad 200 mg plus allopurinol showed no clear difference in proportion with complete resolution of a target tophus compared with placebo plus allopurinol (moderate certainty).
Lesinurad 400 mg plus allopurinol showed no clear difference in proportion with complete resolution of a target tophus compared with placebo plus allopurinol (moderate certainty).
It is very uncertain whether regimens containing clindamycin plus aminoglycoside changes clinical cure according to criteria established by authors… compared with regimens containing quinolone (very low certainty).
Regimens containing clindamycin plus aminoglycoside showed no clear difference in clinical cure according to criteria established by authors Severe PID compared with regimens containing quinolone (low certainty).
It is very uncertain whether regimens containing clindamycin plus aminoglycoside changes adverse events: any antibiotic‐related adverse event leading to… compared with regimens containing quinolone (very low certainty).
It is very uncertain whether regimens containing clindamycin plus aminoglycoside changes microbiological clearance compared with regimens containing quinolone (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Probiotics plus 5‐aminosalicylic acid (5‐ASA) (mesalazine) may leads to higher remission compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
The review found no eligible studies for this question.